Therapie der Mitralklappenendokardiose beim Hund – ein Update

Stephan O. Hungerbühler; Estelle Henrich

doi:10.15654/TPK-170178

Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, Inhaltsverzeichnis

Tierarztl Prax Ausg K Kleintiere Heimtiere 2017; 45(06): 417-427
DOI: 10.15654/TPK-170178

Für Studium und Praxis

Schattauer GmbH

Therapie der Mitralklappenendokardiose beim Hund – ein Update

Therapy of degenerative mitral valve disease in dogs – an update

Authors

Stephan O. Hungerbühler

¹Tiergesundheitszentrum Hungerbühler, Tierärztliche Klinik für Kleintiere Salzgitter
Estelle Henrich

²Klinik für Kleintiere der Justus-Liebig-Universität Gießen

Abstract

Zusammenfassung

Anhand von Anamnese, Signalement, Auskultations- und Röntgenbefund lässt sich bei Hunden die Verdachtsdiagnose der Mitralklappenendokardiose stellen. Die definitive Diagnosestellung und die genaue Bestimmung des Schweregrades erfordern jedoch eine radiologische Größenbeurteilung des Herzens und eine echokardiographische Evaluierung. Mithilfe der Anzeichen der Volumenbelastung kann so zwischen den Stadien B1 und B2 unterschieden werden. Im Stadium A und B1 bedarf es keiner Therapie, eine halbjährliche bis jährliche kardiologische Kontrolle sollte vorgenommen werden, um die Progression der Erkrankung zu beurteilen. Hinsichtlich der Behandlung im Stadium B2 bestand 2009 noch kein Konsens, doch ist heutzutage aufgrund der EPIC-Studie bei diesen Patienten die lebensverlängernde Wirkung von Pimobendan bewiesen. Nach den Resultaten überwiegend experimenteller Studien, in denen sich bei Gabe eines Hemmers des Angiotensin-konvertierenden Enzyms (ACE-H) ein Aldosteron-Escape-Mechanismus ergab, könnte die Hemmung des Renin-Angiotensin-Aldosteron-Systems durch Kombination von ACE-H und Spironolacton ebenfalls schon im Stadium B2 ein vielversprechender Therapieansatz sein. Für eine endgültige Entscheidung bleibt jedoch die DELAY-Stu die abzuwarten. Bei Hunden im akut lebensbedrohlichen dekompensierten Stadium C3 muss zunächst eine Stabilisierung mittels Steigerung der Diurese, positiv inotropen Medikamenten (Pimobendan) und Sauerstoffsubstitution erfolgen. Eine kontinuierliche Kontrolle der wichtigsten Vitalparameter ist durchzuführen. Anhand dieser Befunde wird die Therapie, insbesondere die Dosierung des Diuretikums, angepasst. Daher ist diese Behandlung nur unter intensivme dizinischer Betreuung möglich. Zur Therapie im chronischen Stadium C 1/2 wird das Vierfach-Therapieprotokoll bestehend aus Furosemid, Pimobendan, ACE-H und Spironolacton angeraten. Das Schleifendiuretikum Torasemid stellt dabei eine Alternative zu Furosemid dar. Hunde im Stadium D (trotz medikamentöser Therapie weiterhin refraktäres Herzversagen) sind schwierig zu stabilisieren und haben eine schlechte Prognose. Zur Stabilisierung finden üblicherweise Methoden Anwendung, die bislang nicht evidenzbasiert untersucht wurden.

Summary

Based on history, signalment, auscultation and radiographic examination, the suspected diagnosis of mitral valve endocardiosis can be made in dogs. However, radiological and echocardiographic examinations are necessary for the final diagnosis and can be used to differentiate between stages B1 and B2 through the signs of volume loading. In stages A and B1, no further treatment is required, a 6-month to annual cardiac check should be performed to assess the disease progression. For treatment in the B2 stage, there was no consensus in 2009. However, because of the EPIC study, the life-prolonging effect of pimobendan in dogs in stage B2 has now been demonstrated. According to multiple studies describing an aldosterone escape mechanism when using an angiotensin-converting-enzyme inhibitor (ACE inhibitor), the inhibition of the renin-angiotensin-aldosterone system by a combination of ACE inhibitor and spironolactone appears to be a promising therapeutic strategy in the B2 stage. However, for a final decision, the results of the DELAY Study should be awaited. In dogs with acute decompensation (stage C3), stabilization is required by increasing diuresis, positive inotropic drugs (pimobendan) and oxygen substitution. Continuous monitoring of the most important vital parameters, including capillary refill time, heart rate and rhythm, pulse rate and intensity, respiratory rate and type and neurological status, should be performed. Based on these results, the therapy should be adapted, above all the dosage of the diuretic drug. Therefore, this treatment strategy is only possible under intensive medical care. The quadruple therapeutic protocol consisting of furosemide, pimobendan, ACE inhibitor and spironolactone is recommended for therapy in the chronic stage C 1/2. The diuretic torasemide is a promising alternative to furosemide. Dogs in stage D (refractory cardiac failure despite treatment) are difficult to stabilize and have a poor prognosis. Methods, which have to date not undergone evidence-based evaluation, are normally used for stabilization.

Schlüsselwörter

Herzinsuffizienz - Behandlung - Graduierung - Therapie

Keywords

Heart failure - treatment - grading - therapy

Volltext

Referenzen

Literatur
1 Das Literaturverzeichnis ist online unter. http://dx.doi.org/10.15654/TPK-170178 verfügbar.
1 Ames MK, Atkins CE, Lee S, Lantis AC, zumBrunnen JR. Effects of high doses of enalapril and benazepril on the pharmacologically activated reninangiotensin-aldosterone system in clinically normal dogs. Am J Vet Res 2015; 76: 1041-1050.
2 Ames MK, Atkins CE, Lantis AC, zum Brunnen J. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition. J Renin Angiotensin Aldosterone Syst 2016; 17: 1470320316633897.
3 Asanoi H, Ishizaka S, Kameyama T, Ishise H, Sasayama S. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 1994; 23: 268-274.
4 Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, Hamlin R, Keene B, Luis-Fuentes V, Stepien R. Guidelines for the Diagnosis and Treatment of Canine Chronic Valvular Heart Disease. J Vet Intern Med 2009; 23: 1142-1150.
5 Atkins CE, Keene BW, Brown WA, Coats JR, Crawford MA, DeFrancesco TC, Edwards NJ, Fox PR, Lehmkuhl LB, Luethy MW, Meurs KM, Petrie JP, Pipers FS, Rosenthal SL, Sidley JA, Straus JH. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007; 231: 1061-1069.
6 Atkins CE, Haggstrom J. Pharmacologic management of myxomatous mitral valve disease in dogs. J Vet Cardiol 2012; 14: 165-184.
7 Baumgartner C, Glaus TM. Acquired cardiac diseases in the dog: a retrospective analysis. Schweiz Arch Tierheilkd 2004; 146: 423-430.
8 BENCH (BENazepril in Canine Heart disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999; 1: 7-18.
9 Bernay F, Bland JM, Haggstrom J, Baduel L, Combes B, Lopez A, Kaltsatos V. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24: 331-341.
10 Birocchi S, Cernuschi GC. Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%. Intern Emerg Med 2011; 6: 453-454.
11 Bonagura JD, Twedt DC. Kirk‘s Current Veterinary Therapy XIV. St. Louis, Missouri: Saunders Elseviers; 2009
12 Borgarelli M, Zini E, D‘Agnolo G, Tarducci A, Santilli RA, Chiavegato D, Tursi M, Prunotto M, Haggstrom J. Comparison of primary mitral valve disease in German Shepherd dogs and in small breeds. J Vet Cardiol 2004; 6: 27-34.
13 Borgarelli M, Buchanan JW. Historical review, epidemiology and natural history of degenerative mitral valve disease. J Vet Cardiol 2012; 14: 93-101.
14 Boswood A, Haggstrom J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmari V, Menaut P, Church WM, O‘Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. J Vet Intern Med 2016; 30: 1765-1779.
15 Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995; 206: 194-199.
16 Chetboul V, Lefebvre HP, Sampedrano CC, Gouni V, Saponaro V, Serres F, Concordet D, Nicolle AP, Pouchelon JL. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet Intern Med 2007; 21: 742-753.
17 Chetboul V, Pouchelon JL, Menard J, Blanc J, Desquilbet L, Petit A, Rougier S, Lucats L, Woehrle F. the Tsi. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study. J Vet Intern Med. 2017 DOI:
18 Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507-513.
19 Coussanes E, Williams V, Elliott J, Kaltsatos V. Six month target animal safety study of spironolactone and benazepril hydrochloride combination (Cardalis^®) for oral administration in dogs (Abstract) Poster session of the 12th International Congress of the European Association for Veterinary Pharmacology and Toxicology (EAVPT 2012). Noordwijkerhout, The Netherlands. J Vet Pharmacol Ther 2012; 35: 165.
20 COVE. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group. J Vet Intern Med 1995; 9: 243-252.
21 Dillon AR, Dell’Italia LJ, Tillson M, Killingsworth C, Denney T, Hathcock J, Botzman L. Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs. J Vet Cardiol 2012; 14: 73-92.
22 DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure?. Future Cardiol 2012; 8: 707-728.
23 Erhardt W, Baumgartner C, Henke J, Haberstroh J, Tacke S, Lendl C, Wamser H. Praxisleitfaden Anästhesie und Analgesie: Hund und Katze. Stuttgart: Schattauer; 2013
24 Ettinger SJ, Benitz AM, Ericsson GF, Cifelli S, Jernigan AD, Longhofer SL, Trimboli W, Hanson PD. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc 1998; 213: 1573-1577.
25 Falk T, Jonsson L, Olsen LH, Pedersen HD. Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous mitral valve disease. Cardiovasc Pathol 2006; 15: 185-193.
26 Ferasin L, Crews L, Biller DS, Lamb KE, Borgarelli M. Risk factors for coughing in dogs with naturally acquired myxomatous mitral valve disease. J Vet Intern Med 2013; 27: 286-292.
27 Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag 2009; 5: 21-29.
28 Fox PR. Pathology of myxomatous mitral valve disease in the dog. J Vet Cardiol 2012; 14: 103-126.
29 Fujimoto S, Matsuda T. Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats. J Pharmacol Exp Ther 1990; 252: 1304-1311.
30 Fujimoto S. Effects of pimobendan, its active metabolite UD-CG 212, and milrinone on isolated blood vessels. Eur J Pharmacol 1994; 265: 159-166.
31 Guyonnet J, Elliott J, Kaltsatos V. A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. J Vet Pharmacol Ther 2010; 33: 260-267.
32 Haggstrom J, Hansson K, Kvart C, Swenson L. Chronic valvular disease in the cavalier King Charles spaniel in Sweden. Vet Rec 1992; 131: 549-553.
33 Haggstrom J, Hansson K, Karlberg BE, Kvart C, Madej A, Olsson K. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996; 57: 1645-1652.
34 Haggstrom J, Hansson K, Kvart C, Karlberg BE, Vuolteenaho O, Olsson K. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997; 58: 77-82.
35 Haggström J, Boswood A, O‘Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJL, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O‘Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008; 22: 1124-1135.
36 Hamlin RL, Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. J Vet Intern Med 1998; 12: 93-95.
37 Hezell MJ, Boswood A, Elliot J. Relationships between serum and urinary aldosterone ventricular remodelling and outcome in dogs with mitral valve disease. J Vet Intern Med 2010; 24: 672.
38 Hezzell MJ, Boswood A, Lopez-Alvarez J, Lotter N, Elliott J. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone – a pilot study. J Vet Cardiol 2017; 19: 325-338.
39 Hori Y, Takusagawa F, Ikadai H, Uechi M, Hoshi F, Higuchi S. Effects of oral administration of furosemide and torsemide in healthy dogs. Am J Vet Res 2007; 68: 1058-1063.
40 Hungerbühler S, Henrich E. Die Mitralklappenendokardiose – Aktueller Stand der Diagnose und Therapie. Kleintierprax 2014; 59: 329-352.
41 IMPROVE. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. J Vet Intern Med 1995; 9: 234-242.
42 Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527-1534.
43 King JN, Mauron C, Kaiser G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am J Vet Res 1995; 56: 1620-1628.
44 Kittleson MD, Kienle RD. Small Animal Cardiovascular Medicine. St. Louis: Mosby; 1998
45 Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 1997; 29: 367-372.
46 Kojima K, Nishimura R, Mutoh T, Takao K, Matsunaga S, Mochizuki M, Sasaki N. Comparison of cardiopulmonary effects of medetomidine-midazolam, acepromazine-butorphanol and midazolam-butorphanol in dogs. Zentralbl Veterinarmed A 1999; 46: 353-359.
47 Kvart C, Haggstrom J, Pedersen HD, Hansson K, Eriksson A, Jarvinen AK, Tidholm A, Bsenko K, Ahlgren E, Ilves M, Ablad B, Falk T, Bjerkfas E, Gundler S, Lord P, Wegeland G, Adolfsson E, Corfitzen J. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002; 16: 80-88.
48 Lantis AC, Ames MK, Atkins CE, DeFrancesco TC, Keene BW, Werre SR. Aldosterone breakthrough with benazepril in furosemide-activated reninangiotensin-aldosterone system in normal dogs. J Vet Pharmacol Ther 2015; 38: 65-73.
49 Lantis AC, Ames MK, Werre S, Atkins CE. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs. J Vet Pharmacol Ther 2015; 38: 513-517.
50 Lee JA, Ruegg JC, Allen DG. Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ferret ventricular muscle. Clin Sci (Lond) 1989; 76: 609-618.
51 Lisciandro GR, Lagutchik MS, Mann KA, Voges AK, Fosgate GT, Tiller EG, Cabano NR, Bauer LD, Book BP. Evaluation of a thoracic focused assessment with sonography for trauma (TFAST) protocol to detect pneumothorax and concurrent thoracic injury in 145 traumatized dogs. J Vet Emerg Crit Care 2008; 18: 258-269.
52 Lisciandro GR. The use of the diaphragmatico-hepatic (DH) views of the abdominal and thoracic focused assessment with sonography for triage (AFAST/TFAST) examinations for the detection of pericardial effusion in 24 dogs (2011–2012). J Vet Emerg Crit Care (San Antonio) 2016; 26: 125-131.
53 Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006; 42: 249-261.
54 Manohar M. Pulmonary vascular pressures of strenuously exercising thoroughbreds after administration of flunixin meglumine and furosemide. Am J Vet Res 1994; 55: 1308-1312.
55 McMurray J, Boysen S, Chalhoub S. Focused assessment with sonography in nontraumatized dogs and cats in the emergency and critical care setting. J Vet Emerg Crit Care (San Antonio) 2016; 26: 64-73.
56 McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail 2011; 13: 929-936.
57 Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O‘Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiol 2015; 11: 585-595.
58 Mentz RJ, Buggey J, Fiuzat M, Ersboll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O‘Connor CM, Velazquez EJ. Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. J Cardiovasc Pharmacol 2015; 65: 438-443.
59 Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O‘Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). Am J Cardiol 2016; 117: 404-411.
60 Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, Smith FE, Lane KA, Adams LD, Tierney WM, Brater DC. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111: 513-520.
61 O‘Leary CA, Wilkie I. Cardiac valvular and vascular disease in Bull Terriers. Vet Pathol 2009; 46: 1149-1155.
62 Olsen LH, Fredholm M, Pedersen HD. Epidemiology and inheritance of mitral valve prolapse in Dachshunds. J Vet Intern Med 1999; 13: 448-456.
63 Oyama MA. Neurohormonal activation in canine degenerative mitral valve disease: implications on pathophysiology and treatment. J Small Anim Pract 2009; (50) (Suppl. 01) 3-11.
64 Oyama MA, Peddle GD, Reynolds CA, Singletary GE. Use of the loop diuretic torsemide in three dogs with advanced heart failure. J Vet Cardiol 2011; 13: 287-292.
65 Paulin A, Schneider M, Dron F, Woehrle F. A pharmacokinetic/pharmacodynamic model capturing the time course of torasemide-induced diuresis in the dog. J Vet Pharmacol Ther. 2016
66 Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, Machen MC, Oyama MA. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease. J Vet Cardiol 2012; 14: 253-259.
67 Pedersen HD, Koch J, Poulsen K, Jensen AL, Flagstad A. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency. J Vet Intern Med 1995; 9: 328-331.
68 Pedersen HD. Effects of mild mitral valve insufficiency, sodium intake, and place of blood sampling on the renin-angiotensin system in dogs. Acta Vet Scand 1996; 37: 109-118.
69 Pedersen HD, Olsen LH, Mow T, Christensen NJ. Neuroendocrine changes in Dachshunds with mitral valve prolapse examined under different study conditions. Res Vet Sci 1999; 66: 11-17.
70 Pitt B. „Escape“ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145-149.
71 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
72 Plumb DC. Plumb‘s Veterinary Drug Handbook. Ames, Iowa: PharmaVet, distributed by Wiley; 2011
73 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.
74 Pouchelon JL, Jamet N, Gouni V, Tissier R, Serres F, Carlos Sampedrano C, Castaignet M, Lefebvre HP, Chetboul V. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. J Vet Intern Med 2008; 22: 905-914.
75 Pouleur H, Gurne O, Hanet C, Balasim H, Van Mechelen H, Charlier AA. Effects of pimobendan (UD-CG 115) on the contractile function of the normal and „postischemic“ canine myocardium. J Cardiovasc Pharmacol 1988; 11: 100-106.
76 Pouleur H, Hanet C, Schroder E, Col J, Van Mechelen H, Etienne J, Rousseau MF. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol 1989; 14 (Suppl. 02) S18-22.
77 Schneider M, Bonavaud S, Menard J. et al. Diuretic dosage – equipotency between torasemide and furosemide in healthy dogs. Southern European Veterinary Conference. 2015. Barcelona, Spain.:
78 Schober KE, Hart TM, Stern JA, Li X, Samii VF, Zekas LJ, Scansen BA, Bonagura JD. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 2011; 239: 468-479.
79 Serfass P, Chetboul V, Sampedrano CC, Nicolle A, Benalloul T, Laforge H, Gau C, Hebert C, Pouchelon JL, Tissier R. Retrospective study of 942 small-sized dogs: Prevalence of left apical systolic heart murmur and left-sided heart failure, critical effects of breed and sex. J Vet Cardiol 2006; 8: 11-18.
80 Silverstein D, Hopper K. Small Animal Critical Care Medicine. Elsevier Health Sciences; 2008
81 Sisson DD. Acute and Short-Term Hemodynamic, Echocardiography, and Clinical Effects of Enalapril Maleate in Dogs With Naturally Acquired Heart Failure: Results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril Study: The IMPROVE Study Group. J Vet Intern Med 1995; 9: 234-242.
82 Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 2003; 284: H176-184.
83 Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004; 6: 539-545.
84 Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-2972.
85 Takahashi R, Endoh M. Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. J Cardiovasc Pharmacol 2001; 37: 209-218.
86 Thomason JD, Rockwell JE, Fallaw TK, Calvert CA. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease. J Vet Cardiol 2007; 9: 103-108.
87 Tobias R, Skrodzki M, Schneider M. Kleintierkardiologie kompakt. Schlütersche; 2008
88 Tobias R. Das kardiorenale Syndrom – Die Interaktion von Herz und Nieren beim herzkranken Hund. Kleintierpraxis 2014; 4: 13-22.
89 Tsuda T, Izumi T, Kodama M, Hanawa H, Ohshima M, Takahashi M, Suzuki M, Aizaki T, Uchiyama H, Shibata A. [Acute hemodynamic effects of pimobendan and captopril: a comparative study in the same patients with chronic heart failure]. J Cardiol 1992; 22: 721-729.
90 Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145-150.
91 Uechi M, Matsuoka M, Kuwajima E, Kaneko T, Yamashita K, Fukushima U, Ishikawa Y. The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. J Vet Med Sci 2003; 65: 1057-1061.
92 Uechi M. Mitral valve repair in dogs. J Vet Cardiol 2012; 14: 185-192.
93 Ungemach FR, Kroker R, Lösch W. Pharmakotherapie bei Haus- und Nutztieren. Stuttgart: Enke Verlag; 2010
94 van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989; 14 (Suppl. 02) S1-6.
95 Veinot JP, Johnston B, Acharya V, Healey J. The spectrum of intramyocardial small vessel disease associated with sudden death. J Forensic Sci 2002; 47: 384-388.
96 Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line?. Ann Pharmacother 2009; 43: 1836-1847.
97 Wilke A, Funck R, Rupp H, Brilla CG. Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure. Basic Res Cardiol 1996; 91 (Suppl. 02) 79-84.
98 Woodfield JA. Controlled Clinical Evaluation of Enalapril in Dogs With Heart Failure: Results of the Cooperative Veterinary Enalapril Study Group The COVE Study Group. J Vet Intern Med 1995; 9: 243-252.
99 Yamato M, Sasaki T, Honda K, Fukuda M, Akutagawa O, Okamoto M, Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 2003; 67: 384-390.
100 Yang SS, Han W, Zhou HY, Dong G, Wang BC, Huo H, Wei N, Cao Y, Zhou G, Xiu CH, Li WM. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl) 2008; 121: 38-42.
101 Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.